Medtronic Diabetes Announces CE Mark For New Simplera CGM With Disposable All-In-One Design
Portfolio Pulse from Benzinga Newsdesk
Medtronic Diabetes has received CE Mark for its new Simplera CGM, which is 50% smaller than its previous generation and offers a simple insertion and improved user experience.
September 21, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's new Simplera CGM has received CE Mark, indicating regulatory approval in Europe. This could potentially boost the company's market share in the diabetes care sector.
The CE Mark indicates that Medtronic's new Simplera CGM has met the necessary regulatory requirements in Europe. This approval could potentially increase Medtronic's market share in the diabetes care sector, as the new product offers improvements over the previous generation. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100